Prucalopride succinate for the treatment of constipation: an update.

Abstract

Constipation is a disorder frequently complained about by patients in daily clinical practice. However, to date, its treatment is still commonly unsatisfactory, especially concerning patients' quality of life, when using conventional measures. Prucalopride, a selective 5-hydroxytryptamine receptor 4 agonist, was introduced to the market in 2009 and has been commercially available in Europe since 2010. The main effect of prucalopride is to stimulate colonic motility, which explains its efficacy to treat constipated patients unresponsive to other regimens. Literature search was carried out to look for effects of prucalopride on constipated patients. Several papers were found demonstrating that prucalopride is effective in treatment of constipated patients. Due to its few side effects, the lack of cardiovascular effects and interactions with other drugs, prucalopride may be safely used in elderly people as well.

• Authors: Gabrio Bassotti, Dario Gambaccini, Massimo Bellini
• Journal: Expert review of gastroenterology & hepatology (Expert Rev Gastroenterol Hepatol) Vol. 10 Issue 3 Pg. 291-300 ( 2016) ISSN: 1747-4132 [Electronic] England
• PMID: 26647167 (Publication Type: Journal Article, Review)

Chemical References

• Benzofurans
• Laxatives
• Serotonin 5-HT4 Receptor Agonists
• prucalopride

Topics

• Animals
• Benzofurans (adverse effects, pharmacokinetics, therapeutic use)
• Colon (drug effects, physiopathology)
• Constipation (diagnosis, drug therapy, physiopathology)
• Defecation (drug effects)
• Gastrointestinal Motility (drug effects)
• Humans
• Laxatives (adverse effects, pharmacokinetics, therapeutic use)
• Serotonin 5-HT4 Receptor Agonists (adverse effects, pharmacokinetics, therapeutic use)
• Treatment Outcome